<SEC-DOCUMENT>0001193125-24-203874.txt : 20240821
<SEC-HEADER>0001193125-24-203874.hdr.sgml : 20240821
<ACCEPTANCE-DATETIME>20240820205656
ACCESSION NUMBER:		0001193125-24-203874
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240820
FILED AS OF DATE:		20240821
DATE AS OF CHANGE:		20240820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241226973

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d863387d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as August 20, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d863387dex991.htm">Immutep Announces Late-Breaking Abstract in Head &amp; Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August 20, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d863387dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g863387image1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Late-Breaking Abstract in Head&nbsp;&amp; Neck Cancer Selected </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>for Oral Presentation at ESMO Congress 2024 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Oral presentation will detail results from the randomized <FONT STYLE="white-space:nowrap">TACTI-003</FONT>
Phase IIb trial in first line head</I><I></I><I>&nbsp;&amp; neck squamous cell carcinoma patients with any <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS </I><I><U>&gt;</U></I><I>1)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 20</B><B></B><B>&nbsp;August </B><B>2024 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract has been accepted and selected as a
Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September <FONT STYLE="white-space:nowrap">13-17</FONT> in Barcelona, Spain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The oral presentation will detail results from the randomized Cohort A of the <FONT STYLE="white-space:nowrap">TACTI-003</FONT>
<FONT STYLE="white-space:nowrap">(KEYNOTE-C34)</FONT> Phase IIb trial evaluating eftilagimod alpha (&#147;efti&#148;), a proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with
pembrolizumab versus pembrolizumab alone in recurrent or metastatic first line head and neck squamous cell carcinoma patients with any <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <U>&gt;</U>1). Details of the presentation are as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Primary Results from <FONT STYLE="white-space:nowrap">TACTI-003:</FONT> A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> Plus Pembrolizumab Versus Pembrolizumab
Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS &#8805;1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Speaker:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Claus Andrup Kristensen, MD, PhD, Head of Section for Thoracic and Head and Neck Oncology, Rigshospitalet, Copenhagen, Denmark</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presentation&#8201;#:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">LBA35</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Category:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Proffered Paper session: Head and neck cancer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date&nbsp;&amp; Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sunday, September&nbsp;15, 2024; 10:25 &#150; 10:35 am CET</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Late-breaking abstracts are generally reserved for high-quality, new research findings from randomized phase II or phase III
trials with implications for clinical practice or understanding of disease processes. Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Two ACTive <FONT STYLE="white-space:nowrap">Immunotherapies-003</FONT> <FONT STYLE="white-space:nowrap">(TACTI-003)</FONT> trial is an ongoing Phase IIb
study (also known as KEYNOTE-C34) evaluating eftilagimod alpha (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co.,
Inc., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line treatment of recurrent or
metastatic head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with
<FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (Combined Positive Score [CPS] &#8805;1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative
tumours (CPS &lt;1). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g863387image1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Objective Response Rate of evaluable patients according to RECIST 1.1. Secondary
endpoints include Overall Survival, Objective Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; catherine.strong@sodali.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; chris.basta@immutep.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g863387image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g863387image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"F17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0?.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1H87)A:V$@
M1&4@4VEL=F$    !ZAP !P  " P   AN     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"BM"Z5&-)6044459L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'F?C__ )&1?^O=?YFNI\5_\B2_
M^[%_Z$M<MX__ .1D7_KW7^9KJ/%?_(D2?[L7\Q7/UD><MZI1^'7_ "#KW_KN
M/_016=\0QC5+-AU\D\_\"K2^'/\ R#;W_KL/_0:H?$?_ )"%C_UR;^8H?\(4
MO]T7]=3KM".[P[I^>?\ 1X__ $$5Y^ %^(>U>G]H?^S"O0?#_P#R+FG_ /7N
MG\JX!_\ DI'_ &_C_P!"ISVB77^&'JC;^(O_ !Z:?_UU;^5;'@W_ )%.S/\
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M_P :F'Q<T_RLG3+D28^Z'7'Y_P#UJZCPMX@'B71S?"#R,2M'Y>[=C&._T(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"[N0H]@./U[T >.^&8TE^)Z1RHKHUU.&5AD'A^U>KKX4T!9A*NCV0<'(Q"N
M?ITKRKPK_P E3B_Z^Y_Y/7M= "*H50J@ #@ #I2T44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -:-&;+(K'U(I=HP1@<]?>EHH :T:.H5T5@.@(S3L444 -2-(Q
MA%51[#%.QSFBB@!-HQC''I2X Z"BB@ P,YQR::B+&,(H4>@&*=10 8I"BE@Q
M4%AT..12T4 &,T8&<]Z** &M&C@!T5@.@(SBE"J     ,#CI2T4 &!G..:3
M]!US2T4 '7K1CC HHH 8(HP^X(N[KG'-/HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'UE_P"_O_UZ/(U'UE_[^_\ UZ**.4/9KN'D:CZR_P#?W_Z]'D:CZR_]_?\
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M2_\ ?W_Z]'D:G_>E_P"_O_UZ**.4/9KN'D:G_>E_[^__ %Z/(U/^]+_W]_\
MKT44<H>S7</(U/\ O2_]_?\ Z]'D:G_>E_[^_P#UZ**.4/9KN'D:G_>E_P"_
MO_UZ/(U/^]+_ -_?_KT44<H>S7</(U/^]+_W]_\ KT>1J?\ >E_[^_\ UZ**
M.4/9KN'D:G_>E_[^_P#UZ/(U/^]+_P!_?_KT44<H>S7</(U/^]+_ -_?_KT>
M1J?]Z7_O[_\ 7HHHY0]FNX>1J?\ >E_[^_\ UZ/(U/\ O2_]_?\ Z]%%'*'L
MUW#R-3_O2_\ ?W_Z]'D:G_>E_P"_O_UZ**.4/9KN'D:G_>E_[^__ %Z/(U/^
M]+_W]_\ KT44<H>S7</(U/\ O2_]_?\ Z]'D:G_>E_[^_P#UZ**.4/9KN'D:
MG_>E_P"_O_UZ/(U/^]+_ -_?_KT44<H>S7</(U/^]+_W]_\ KT>1J?\ >E_[
M^_\ UZ**.4/9KN'D:G_>E_[^_P#UZ/(U/^]+_P!_?_KT44<H>S7</(U/^]+_
M -_?_KT>1J?]Z7_O[_\ 7HHHY0]FNX>1J?\ >E_[^_\ UZ/(U/\ O2_]_?\
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D44<H>S7</(U'UE_[^_\ UZ/(U'UE_P"_O_UZ**.4/9KN?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
